Thermo Fisher Scientific opens new steriles drug manufacturing site in Singapore

L-R: Tan Kong Hwee, Executive Vice President of Singapore Economic Development Board; Sho-Wen Yeo, Vice President and General Manager of Southeast Asia and Taiwan, Thermo Fisher Scientific; Tony Acciarito, President, Asia Pacific & Japan, Thermo Fisher; Png Cheong Boon, Chairman of Singapore Economic Development Board; Deputy Prime Minister of Singapore Heng Swee Keat; Michel Lagarde, Executive Vice President and Chief Operating Officer, Thermo Fisher; Goh Wan Yee, Senior

The life science service and instrument provider have opened their new Singapore-based steriles drug manufacturing facility with the goal of bringing increased development and manufacturing capabilities for critical medicines to the APAC region. 

The facility was established with help from the Singapore Economic Development Board to align with the Singaporean government’s investment into future health emergencies; the facility will provide rapid fill-finish capabilities for vaccines, along with end-to-end pharmaceutical development and manufacturing services. This will be achieved with a high-speed fully automated aseptic fill-finish line for both small and large molecule therapeutics, and will join Thermo Fisher’s increased research capabilities at two other operational lab facilities (the Customer Experience Center and the Bioprocess Design Center), showcasing the latest in bioprocessing, life science, and analytical technologies. The facility will be the first in Singapore to offer live virus capabilities.

 Sterile drug products are manufactured through aseptic processing at Thermo Fisher’s fill-finish site in Singapore   

Thermo Fisher’s Customer Experience Center offers over 250 products across molecular biology, genetic analysis and sequencing, chromatography and mass spectrometry, and cell therapy, and will provide an extensive product portfolio to the APAC region. Their Bioprocess Design Center additionally provides bioprocessing and process scale-up expertise and customised services to scientists and engineers looking to accelerate process development.  

Executive VP and COO at Thermo Fisher Scientific Michel Lagarde commented: “We are committed to serving as a reliable partner to the Asia-Pacific region and the world. This new site is an important extension of Thermo Fisher’s robust sterile fill-finish global network. With this expansion, we are strategically prepared, more than ever, to respond to our customers’ needs by supporting the accelerated delivery of critical vaccines and medicines to patients.” 

Png Cheong Boon, Chairman of the Singapore Economic Development Board, added: “Singapore’s strengths in manufacturing and connectivity to the region make us a hub for the production and supply of important pharmaceutical drugs to service Asia’s healthcare needs. Thermo Fisher Scientific’s fill-finish manufacturing facility will enable end-to-end vaccine manufacturing to be carried out in Singapore. This will strengthen our vaccine supply chain resilience and enhance future pandemic preparedness for our region.” 

Source: Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region [Accessed May 23, 2023] https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2023/Thermo-Fisher-Scientific-Expands-Steriles-Manufacturing-and-Research-Capabilities-in-Asia-Pacific-Region/default.aspx